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AbstrAct
Mutations in the Ataxia-telangiectasia mutated (ATM) gene are frequently 
found in human cancers, including non-small cell lung cancer (NSCLC). Loss of ATM 
function confers sensitivity to ionising radiation (IR) and topoisomerase inhibitors 
and may thus define a subset of cancer patients that could get increased benefit from 
these therapies. In this study, we evaluated the phenotypic consequences of ATM 
missense changes reported in seven NSCLC cell lines with regard to radiosensitivity 
and functionality of ATM signalling. Our data demonstrate that only 2/7 NSCLC 
cell lines (H1395 and H23) harbouring ATM missense mutations show a functional 
impairment of ATM signalling following IR-exposure. In these two cell lines, the 
missense mutations caused a significant reduction in ATM protein levels, impairment 
of ATM signalling and marked radiosensitivity. Of note, only cell lines with homozygous 
mutations in the ATM gene showed significant impairment of ATM function. Based on 
these observations, we developed an immunohistochemistry-based assay to identify 
patients with loss or reduction of ATM protein expression in a clinical setting. In a 
set of 137 NSCLC and 154 colorectal cancer specimens we identified tumoral loss of 
ATM protein expression in 9.5% and 3.9% of cases, respectively, demonstrating the 
potential utility of this method.
INtrODUctION
Lung cancer is the most common cancer type and, 
at the same time, has one of the lowest survival outcomes, 
rendering it the leading cause of cancer-related mortality 
worldwide [1]. Most lung cancer patients are treated 
with DNA-damaging modalities such as chemotherapy 
and ionising radiation (IR). Although effective, these 
treatments generally lack selectivity towards cancer cells 
resulting in normal tissue toxicity and potentially severe 
side effects, which are limiting factors for both the dose 
and duration of therapy [2, 3]. These limitations are one 
of the reasons why these genotoxic therapies are rarely 
curative and a substantial amount of research in recent 
years has focused on the identification of potential 
combination approaches and new molecular targets that 
may enhance the anti-tumour efficacy of chemo- or 
radiotherapy without increasing normal tissue toxicity. A 
promising target for this approach is the kinase Ataxia-
telangiectasia mutated (ATM). 
ATM is one of the principal mediators of the DNA 
damage response (DDR), a complex network of signalling 
pathways that mediates the detection and repair of DNA 
damage and the enforcement of DNA damage-induced 
cell cycle checkpoints [4-6]. Germline mutations in the 
ATM gene are responsible for the autosomal recessive 
human hereditary disorder Ataxia-telangiectasia (A-
T). This disease, caused by a loss of ATM function, is 
characterised by progressive cerebellar degeneration, 
telangiectasia, immunodeficiency, growth retardation, 
genomic instability, cancer susceptibility and profound 
sensitivity to IR [4, 7-9]. Notably, somatic mutations in 
the ATM gene have been reported in a broad range of 
human cancers including colorectal [10], breast [11] and 
haematopoietic cancers [12, 13] as well as in 5.1-9.1% 
of lung cancer cases [14, 15]. Considering the substantial 
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sensitivity to IR, radiomimetic drugs and topoisomerase 
inhibitors observed in cells derived from A-T patients [7, 
16, 17], tumoral loss of ATM function may define a subset 
of patients that could get increased benefit from such 
treatments. 
Amongst the cancer-associated ATM mutations are 
truncating, frame-shift or splice site mutations, which are 
likely to affect ATM function and/or protein expression 
(Figure 1a) [18]. However, a considerable proportion 
(~70%) of the ATM mutations reported in cancer to date 
are missense changes, which lead to the substitution of a 
single amino acid. These mutations arise across the entire 
length of the ATM protein, with no apparent hotspots (with 
the possible exception of the R337 site; Figure 1a) [19, 
20]. Considering the large size of the ATM gene (150 kb of 
genomic DNA) and the characteristic genomic instability 
of cancer cells, it is likely that a proportion of the occurring 
missense mutations are neutral passenger mutations 
[21]. Distinguishing such passenger mutations from 
deleterious missense mutations is currently not possible 
without functional studies. An additional hindrance in 
the assessment of the functional consequences of ATM 
mutations is the evaluation of zygosity, as cancer cells are 
frequently aneuploid and even deleterious mutations might 
not result in any phenotypic consequences if one or several 
wildtype (wt) alleles are present.
The studies presented here were designed to address 
two issues. Firstly, given that most cancer-associated 
ATM mutations are missense variants whose functional 
consequences have not yet been elucidated, we performed 
phenotypic studies in a panel of seven NSCLC cell lines, 
which have been reported to harbour missense changes in 
the ATM gene (Table 1). We demonstrate that certain ATM 
missense changes lead to a loss of ATM protein expression 
and functional impairment of ATM. However, only 2/7 
ATM-mutated cell lines (H23 and H1395) exhibited a 
gross functional impairment of ATM. In contrast, the ATM 
missense changes in the remaining five cell lines (HCC-
366, H1568, H1734, H520 and H2087) appeared to have 
no or only limited impact on overall ATM function in 
response to IR. These observations can likely be attributed 
to differences in zygosity as we found that only in those 
cases where ATM missense mutations were homozygous 
did cell lines display phenotypic changes characteristic of 
a loss of ATM function. 
Secondly, we aimed to address the question, 
how patients with loss or impairment of ATM activity 
could be identified in a clinical setting. For this 
purpose, we analysed ATM protein expression by 
immunohistochemistry (IHC) in human NSCLC and 
colorectal cancer (CRC) specimens. We found that ATM 
protein expression was frequently lost or reduced in cancer 
cells (but not stromal cells), suggesting that IHC analysis 
of ATM protein expression may constitute a valuable tool 
to identify patients with loss of ATM function. 
rEsULts AND DIscUssION
AtM missense mutations found in NscLc can 
lead to a reduction in AtM protein levels and 
impairment of the AtM signalling pathway
Advancements in DNA sequencing technologies 
have allowed for the identification of numerous genes and 
gene products crucially involved in cancer development 
and for many oncogenes or tumour suppressor genes, the 
functional consequences of recurrent hotspot mutations 
have been well characterised. For ATM, a putative tumour 
suppressor, this is not the case. Somatic mutations in 
the ATM gene have been identified in a range of cancer 
types, including NSCLC, and also in several established 
and widely used NSCLC cell lines [22-24]. We selected 
seven of those cell lines, which have been reported to 
harbour homo- (H23 and H1395) or heterozygous (HCC-
366, H1568, H1734, H2087 and H520) ATM missense 
substitutions (see Figure 1b, and Table 1). We verified the 
presence of the reported mutations by Sanger sequencing 
(Figure 1c and S1) and calculated the PolyPhen-2 
(Polymorphism phenotyping version 2) scores for the 
missense changes [25]. PolyPhen-2 is a software tool, 
which uses sequence- and structure-based information to 
predict the possible impact of an amino acid substitution 
on the structure and function of a human protein. With 
the exception of the c.8895 G > C (p.L2965F) mutation 
reported in H2087, the presence of all previously reported 
mutations could be validated. Several of the identified 
missense changes were predicted to affect protein function 
based on the PolyPhen algorithm (Table 1). 
Studies on the characterisation of cellular defects 
caused by ATM-deficiency in cells derived from Ataxia-
telangiectasia patients have led to the discovery of 
phenotypes and biomarkers associated with functional 
impairment of ATM [4]. To study the phenotypic 
consequences of the identified ATM missense substitutions 
with regard to radiosensitivity and functionality of ATM 
signalling following IR-exposure, we first determined 
total ATM protein levels, as well as ATM kinase activity, 
following exposure of the cells to 10 Gy IR by western 
blot analysis. Widely used biomarkers to evaluate 
activity of the ATM signalling pathway include ATM 
autophosphorylation at serine 1981, which is considered 
to be associated with ATM activation [26], as well as IR-
induced phosphorylation of the ATM downstream targets 
KAP1 (S824), SMC1 (S966), NBS1 (S343), p53 (S15) and 
CHK2 (Thr68) [27, 28]. In addition to the ATM-mutated 
cell lines, the ATM wild-type cell lines COR-L105, A549 
and H1299 were used as controls. Levels of the respective 
total and phospho-proteins in these cell lines served as 
reference levels for normal ATM kinase activity. The 
fibroblast cell line GM05849, which was derived from an 
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A-T patient and exhibits no ATM protein expression, was 
used as ATM-negative control [29].
As anticipated, the A-T fibroblast cell line 
GM05849 showed no ATM protein expression and no 
phosphorylation of the ATM downstream targets KAP1, 
SMC1, NBS1 or CHK2 in response to IR (Figure 2a). 
Notably, only low levels of total ATM protein were 
evident in the H1395 and H23 cell lines. All other cell 
lines showed levels of ATM protein expression that were 
comparable to the control cell lines COR-L105 or A549. 
Following exposure to IR, a robust increase in the levels 
of ATM activation and phosphorylation of several ATM 
downstream targets was evident in the A549, COR-L105 
and H1299 control cell lines within 60 minutes post-
irradiation. HCC-366, H1568, H2087, H1734 and H520 
cells also displayed normal kinase activity for both ATM 
itself, as well as its downstream targets (Figure 2a). 
Consistent with the low total ATM protein levels 
observed in H1395 and H23 cells, the radiation-induced 
kinase activity of ATM was severely impaired, as seen 
by an inability to induce ATM autophosphorylation or 
phosphorylation of the ATM downstream targets KAP1, 
SMC1 and NBS1 in response to IR. As the H23 cell line 
also harbours a mutation in the TP53 gene (p.M246I), 
aberrant levels of total and phosphorylated p53 were 
observed in this cell line (Figure 2a). No (H1299) or 
aberrant phospho- and total p53 protein levels were also 
observed in the other p53-mutated NSCLC cell lines 
(HCC-366, H1568, H1734, H2087 and H520) and the 
SV-40 transformed GM05849 cell line, independent of 
radiation treatment. 
It should be noted, that the phosphorylation levels 
of several ATM downstream targets, like NBS1 or CHK2, 
differed between cell lines and not all downstream targets 
were phosphorylated to a comparable extent in each cell 
line. COR-L105, for example, displayed a marked increase 
in the phosphorylation of ATM, KAP1, SMC1 and CHK2, 
but only a modest increase in the phosphorylation of 
NBS1. H1568 cells on the other hand, showed only a 
modest increase in KAP1 phosphorylation levels, but a 
robust increase in pATM, pSMC1, pNBS1 and pCHK2 
levels. These differences are likely due to differences in 
the cell biology that result from unique combinations 
of somatic mutations and epigenetic alterations causing 
cancer cell line specific levels of replication stress, 
genomic instability and activity levels of certain signalling 
pathways. Furthermore, several of the downstream targets 
of ATM are shared targets of other DDR kinases, such as 
DNA-PKcs and ATR. In order to assess the kinase activity 
of ATM following exposure to IR, it therefore seems 
plausible and necessary to determine the phosphorylation 
levels of a combination of several ATM downstream 
targets. 
ATM-deficient cancer cells are highly sensitive to 
Ir
One of the most prominent phenotypes of ATM-
deficient cells is a hypersensitivity to IR [7]. We therefore 
determined the survival and colony forming ability of 
the cell lines following exposure to IR. The clonogenic 
table 1: AtM missense changes reported in NscLc cell lines and predicted functional consequences based on 
PolyPhen scoring.
cell line sequence change
Amino acid 
substitution
(zygosity)
Location PolyPhen-2 assessment (score)
H2087 c.2542G>C p.E848Q(heterozygous) N-terminal benign (0.025)
H2087 c.8895G>C † p.L2965F(heterozygous)
just C-terminal of 
PI3K domain probably damaging (0.992)
H23 c.5756A>C p.Q1919P(homozygous) FAT domain probably damaging (1.000)
H1395 c.7996A>G p.T2666A(homozygous)
just N-terminal of 
PI3K domain probably damaging (1.000)
H520 c.1147C>G p.P383A(heterozygous) N-terminal benign (0.000)
H1734 c.194A>C p.Q65P(heterozygous) N-terminal probably damaging (0.987)
H1568 c.1516-1517GG>TT
p.G506F
(heterozygous) N-terminal possibly damaging (0.842)
HCC-366 c.1600C>G p.P534A(heterozygous) N-terminal probably damaging (1.000)
† We were unable to validate the presence of this mutation, as Sanger sequencing showed homozygosity for the wildtype 
sequence in this position (see Figure S1).
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survival assays provided further evidence for a functional 
loss of ATM in H1395 and H23 cells, as both cell lines 
exhibited substantial radiosensitivity compared with the 
A549, COR-L105 or H1299 control cell lines. H2087, 
HCC-366, H520 and H1568 cells, on the other hand, 
showed similar IR-sensitivity to control cells or an 
intermediate sensitivity (Figure 2b). The H1734 cell line 
did not form colonies suitable for clonogenic survival 
assays and was thus excluded from this part of our study. 
To assess whether there might be a correlation 
between radiosensitivity and the expression levels or 
activity of ATM, we quantified the protein expression 
data obtained from western blot analysis using the ImageJ 
software. ATM protein expression, or the -fold induction 
of ATM autophosphorylation after IR-exposure, were 
plotted against the surviving fraction of the cells at 2 
Gy, calculated from clonogenic survival assays (Figure 
2c, 2d). The data indicated a strong positive linear 
correlation between ATM protein expression levels and 
radiosensitivity (R = 0.8832). For the -fold induction of 
ATM autophosphorylation levels after IR-exposure and 
radiosensitivity, the correlation was less pronounced, yet 
still considerable (R = 0.6825). A similar correlation with 
radiosensitivity was found for KAP1 S824 levels 60 min 
after irradiation (R = 0.65). For pCHK2 Thr68 levels, 
however, no significant correlation was found (R = 0.31; 
Figure S2). 
For further evaluation of the effect of ATM protein 
expression levels on radiation sensitivity, we compared 
the clonogenic survival of stable ATM knockdown cell 
Figure 1: Distribution and types of AtM mutations in different cancer types. FAT (FRAP-ATM-TRRAP domain), FATC 
(FAT C-terminal domain), PIKK (phosphatidylinositol 3-kinase-related kinase domain), TAN (Tel1/ATM N-terminal motif).a. Schematic 
representation of the ATM protein with the positions of 722 ATM mutations reported in 108 representative cancer genomics studies 
highlighted below. Data analysis and visualisation were performed using the cBioPortal Cancer Genomics tool (http://www.cbioportal.
org; access on 22.01.2016) [19, 20] and the results shown here are in part based upon data generated by the TCGA Research Network: 
http://cancergenome.nih.gov/. b. Distribution of ATM missense changes in NSCLC cell lines. Schematic representation of the ATM protein 
displaying the positions of homo- or heterozygous ATM missense changes reported in the 7 NSCLC cell lines used in this study. c. DNA 
sequencing results showing the presence of a homozygous c.7996 A > G (p.T2666A) and c.5756 A > C (p.Q1919P) missense mutation 
(arrows) in the ATM gene in the H1395 and H23 cell line, respectively. Wildtype sequences derived from H1299 cells are shown on the left. 
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lines and the corresponding controls following exposure 
of cells to IR (Figure 3). We found that ATM knockdown 
markedly increased the cytotoxic effects of IR in all cell 
lines, however, the effect was much greater in the cell line 
with the highest degree of ATM knockdown (COR-L105 
- no detectable ATM protein or phosphorylation of ATM/
KAP1/SMC1 following IR; Figure 3a, 3b) compared with 
those cell lines that showed low residual amounts of ATM 
protein and kinase activity (H2087 and H1299 - residual 
ATM, KAP1 and SMC1 phosphorylation; Figure 3c-3f). 
Taken together these observations suggest that 
expression levels of ATM protein correlate well with the 
sensitivity of cancer cell lines to IR, and might thus be 
a useful biomarker to predict responses to radiotherapy. 
Figure 2: the effect of AtM missense changes on AtM protein levels, kinase activity and cellular radiosensitivity. 
a. To assess the activity of the ATM signalling pathway following exposure of cells to IR, three ATM wildtype and seven ATM mutated 
NSCLC cell lines were mock-irradiated (control) or irradiated with 10 Gy followed by preparation of protein lysates 60 min after IR. The 
A-T fibroblast cell line GM05849 served as ATM-negative control. ATM autophosphorylation (S1981) and phosphorylation of several ATM 
downstream targets were monitored by western blot analysis. β-Actin and α-Tubulin were measured to ensure equal loading. b. Clonogenic 
survival of the NSCLC cell lines used in a) following exposure to the indicated doses of IR. Each point represents the mean of at least three 
independent experiments, each performed in triplicate ± SEM. c. ATM protein expression measured by western blot was quantified using 
the ImageJ software and plotted together with the surviving fraction at 2 Gy of the respective cell line. ATM protein expression values 
are normalised to β-Actin levels and expressed as the mean of control and IR-treated sample for each cell line. d. The increase in ATM 
autophosphorylation levels measured by western blot for each cell line was quantified and plotted as in c). ATM S1981 levels (60 min after 
10 Gy IR) are normalised to β-Actin levels of the respective sample and expressed as a fold increase of the IR-treated sample compared 
with unirradiated control for each cell line.
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Figure 3: AtM knockdown in NscLc cells reduces the Ir-induced phosphorylation of AtM targets and increases 
radiosensitivity. a., c. and e. COR-L105, H1299 and H2087 cells, stably transfected with ATM short hairpin RNA (shATM) or the 
respective control plasmid (shGFP), were mock-irradiated (control) or irradiated with 10 Gy followed by preparation of protein lysates 60 
min after irradiation. β-Actin was measured to ensure equal loading. b., d. and f. Clonogenic survival of the indicated cell lines following 
exposure to IR. Each point represents the mean of three independent experiments, each performed in triplicate. 
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Assessment of the phosphorylation of ATM downstream 
targets, on the other hand, appears to be less reliable in 
the prediction of radiosensitivity, which could be due to 
differences in phosphorylation kinetics between cell lines 
or overlap with other DDR pathways, which converge in 
the same downstream targets (e.g. DNA-PKcs or ATR 
signalling). 
In order to validate that the observed high degree 
of radiosensitivity in H1395 and H23 cells was due to 
impaired ATM function, we assessed clonogenic survival 
of cells treated with a combination of IR and the specific 
ATM inhibitor KU55933, or the DNA-PKcs inhibitor 
NU7441, which served as a radiosensitizer control [30]. 
We hypothesised that, if the observed radiosensitivity 
of H1395 and H23 cells was due to defects in ATM 
signalling, treatment of cells with an ATM inhibitor 
would produce no additional effect on radiation-induced 
cytotoxicity in these cells.
Consistent with loss of ATM function, exposure 
of H1395 and H23 cells to the ATM inhibitor did not 
significantly further increase the cytotoxic effects of IR 
(H23 p = 0.06; H1395 p = 0.8) (Figure 4a). The small 
degree of radiosensitisation by KU55933 observed in 
H23 cells (p = 0.06) is possibly due to residual amounts 
of functional ATM in this cell line. Normal bronchial 
epithelial cells (NBE1), as well as COR-L105, H1299 
and H2087 cells, on the other hand, were profoundly 
radiosensitised by KU55933 treatment (p-values < 0.001 
for all four cell lines). DNA-PKcs inhibition significantly 
radiosensitised all cell lines (Figure 4a; p-values < 
0.001 for all cell lines). We also determined the effect of 
pharmacological ATM inhibition on the radiosensitivity 
of the remaining ATM-mutated cell lines. In all three 
cell lines (HCC-366, H520, H1568), KU55933 treatment 
significantly increased the radiation-induced cytotoxicity 
(p-values < 0.001 for all three cell lines), while the 
ATM-negative GM05849 fibroblast cell line showed no 
radiosensitisation (p = 0.993; Figure 4b). 
ATM-deficient cancer cells exhibit cell cycle 
checkpoint defects
Loss of ATM function is known to lead to defects 
in cell cycle checkpoint activation in response to DNA 
damage. In particular, these checkpoint defects include an 
impaired cell cycle arrest at the G1/S boundary following 
DNA DSB induction, which is also a characteristic of p53-
deficient cells [31], as well as an inability to slow on-going 
DNA replication in cells exposed to IR, a phenomenon 
described as radiation-resistant DNA synthesis [32-34]. 
To further evaluate potential defects in ATM 
function, we analysed cell cycle checkpoint activation in 
cells exposed to IR, using flow cytometry. We performed 
BrdU pulse labelling of COR-L105, H1395 and H2087 
cells to detect S-phase populations following IR treatment 
(Figure 5). In COR-L105, a reduction in the proportion 
of BrdU-labelled cells in early S-phase within 6 h post-
irradiation was evident, indicating activation of the G1/S 
checkpoint, which prevents cells with damaged DNA from 
entering S-phase and is typical for p53 and ATM wt cells 
(Figure 5a). In contrast, H1395 and H2087 cells showed 
no or only a minimal decrease in BrdU-labelled cells in 
early S-phase after irradiation, suggesting that these cells 
failed to induce the G1/S cell cycle checkpoint, consistent 
with a functional impairment of ATM or p53. Over time, 
an accumulation of cells in G2 was evident in both cell 
lines (Figure 5b, 5c), representing the activation of a 
G2/M cell cycle arrest following IR. While H2087 cells 
displayed a significant increase in the overall S-phase 
population during early time-points after IR, indicating 
a slowdown of S-phase progression, this effect was 
less pronounced in H1395 cells (Figure 5b), consistent 
with a defect in ATM signalling in H1395, resulting in 
radioresistant DNA synthesis. 
Taken together these results demonstrate that the 
homozygous p.T2666A (H1395) and p.Q1919P (H23) 
missense substitutions in the ATM gene lead to a strong 
reduction in ATM protein levels and severe impairment 
of the ATM signalling pathway, indicating that these are 
deleterious mutations. The NSCLC cell line H2087 has 
been reported to carry two heterozygous ATM missense 
substitutions (p.E848Q and p.L2965F) [22-24]. According 
to PolyPhen-2 one of these mutations was predicted to be 
benign, while the other one was likely to be damaging 
(Table 1). However, we were not able to verify the 
presence of the potentially damaging p.L2965F mutation 
and our results demonstrate that this cell line exhibits 
normal ATM-dependent signalling in response to IR, as 
well as increased radiosensitivity following treatment with 
an ATM inhibitor or knockdown of ATM protein. These 
observations suggest that the ATM missense substitution 
present in this cell line is either a benign passenger 
mutation, or, if it is a deleterious mutation, that the 
remaining wildtype allele allows for sufficient expression 
of functional ATM to retain activity. Similar results were 
obtained in four other NSCLC cell lines, which have 
been reported to harbour ATM missense changes, some 
of which were predicted to be damaging according to 
PolyPhen-2 (HCC-366, H1568, H1734 and H520; Table 
1). Altogether, the PolyPhen-2 prediction only supported 
the results from phenotypic analyses in the case of 4 out 
of 7 ATM mutations (57%). However, as the reported 
ATM mutations in these cell lines are heterozygous 
(with allele frequencies between 0.23 and 0.78) [23], it 
is possible that the remaining wildtype ATM alleles are 
sufficient to allow for normal ATM expression levels 
and function. Supportive evidence for this hypothesis 
comes from studies in patients with chronic lymphocytic 
leukaemia containing a deletion of the ATM gene locus 
(11q deletion) which demonstrated, that the remaining 
ATM wildtype allele had to be mutated in order to see a 
functional impairment of ATM signalling [35]. This raises 
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Figure 4: ATM-deficiency confers sensitivity to IR, which is not further increased by addition of the ATM inhibitor 
KU55933. a. Clonogenic survival of normal bronchial epithelial (NBE1) and NSCLC cells following exposure to IR alone, or in 
combination with ATM (KU55933; 10 µM) or DNA-PK (NU7441; 500 nM) inhibition. Cells were pre-treated with the inhibitors for 1 h 
prior to irradiation and treatment was continued for 24 h. Each point represents the mean of three independent experiments, each performed 
in triplicate. Statistically significant differences (univariate ANOVA) between survival curves are indicated with ** = p-values < 0.001 
and *** = p-values < 0.0001. b. Clonogenic survival of GM05849, HCC-366, H520 and H1568 cells following exposure to IR alone, or in 
combination with the ATM inhibitor KU55933 (10 µM). Treatment, display of results and statistical analysis as in a).
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the question, whether heterozygosity of ATM mutations 
in cancer cells is generally associated with retained ATM 
activity. Future studies will have to address this question 
and establish, whether mutant ATM protein can act in a 
dominant-negative way and if so, which mutations would 
lead to this phenotype. Nevertheless, our results suggest 
that in the case of heterozygous ATM mutations, software 
tools like PolyPhen-2 are only of limited use to predict the 
phenotypic consequences of a given missense mutation, 
due to the recessive nature of functional loss in the case of 
ATM. Our results thus demonstrate, that the occurrence of 
a somatic ATM mutation in a cancer cell does not imply an 
impairment or loss of ATM function. 
When performing functional studies, we focussed 
on the activity and functionality of the ATM signalling 
pathway in response to IR, as radiotherapy is one of the 
most commonly used therapies for lung cancer patients 
and the ATM-dependent response of cells to IR has been 
Figure 5: ATM deficiency leads to attenuation of the G1/S and intra-S-phase checkpoints. Asynchronous populations of a. 
COR-L105, b. H1395 and c. H2087 cells were mock-irradiated or irradiated with 10 Gy. After irradiation, cells were incubated at 37°C for 
the indicated times before being pulse-labelled with BrdU for 20 min. Cells were then harvested, fixed, and stained with PI and anti-BrdU 
antibody for FACS analysis. BrdU staining (left-hand panels) and PI-staining (right-hand panels) are representative of two and at least 
three independent experiments, respectively. The upper gates represent (from left to right) early-S-, intra-S- and late-S- /early G2-phase 
cell populations.
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well characterised. However, it is possible that some of 
the mutations only affect the binding of ATM to certain 
substrates, which would consequently only alter certain 
arms of the ATM signalling network or the activity of 
ATM in a specific context, for example in response to 
reactive oxygen species [26, 36]. As ATM has been 
reported to have approximately 1000 downstream targets 
[37], extensive phospho-proteomic studies would be 
required to investigate the effect of each ATM mutation 
on the overall activity of ATM.
Identification of ATM-deficiency in a clinical 
setting
As ATM-deficiency confers a high sensitivity to IR, 
radiomimetic drugs and topoisomerase inhibitors [7, 16, 
17], it would be of clinical significance - and help guide 
the process of identifying the best treatment option for 
patients - to be able to differentiate between benign and 
deleterious, as well as homo- and heterozygous, mutations. 
However, the ATM gene extends over approximately 
150 kb of genomic DNA, contains 66 exons and 
encodes for a 3056 amino acid protein [38]. This large 
size of the ATM gene renders routine DNA sequencing 
a challenging diagnostic tool to identify patients with 
ATM-deficiency and stromal contamination of samples 
hinders the determination of zygosity. Furthermore, as 
our results clearly show, the presence of an ATM mutation 
does not necessarily imply that there will be a functional 
impairment of ATM signalling, particularly in the case of 
heterozygous missense changes. Therefore, we aimed to 
address the question, how patients with tumoral loss of 
ATM function could be identified in a clinical setting. 
Studies on ATM missense mutations found in 
A-T patients have shown that the majority of missense 
mutations which lead to functional impairment of ATM 
do so by de-stabilising the protein, leading to reduced or 
Figure 6: ATM protein expression in NSCLC cell lines assessed by immunohistochemistry. A panel of 35 NSCLC cell 
lines was analysed for ATM protein expression by IHC. The A-T fibroblast cell line GM05849 was included as ATM-negative control. 
Representative images of the cell lines used in this study are shown. Pictures were taken at a 400x magnification. Scale bar = 50 µm. A 
detail magnification is shown in the upper right corner of each picture.
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absent protein levels [18, 27, 28, 39-41]. Our data suggests 
that the same principle may apply to cancer-associated 
ATM missense mutations, as we identified two NSCLC 
cell lines harbouring homozygous missense mutations 
in the ATM gene (H1395 and H23) with impaired ATM 
function. In both cases, mutation was associated with 
markedly reduced ATM protein expression. To our 
knowledge, mutations leading to expression of a kinase- 
dead (kd) ATM protein have only rarely been reported in 
cancer [42] and none of them in NSCLC. 
To address this possibility further, we evaluated 
immunohistochemical (IHC) staining of ATM in human 
tumour samples as a potential method for the identification 
of patients with a loss or reduction of ATM function. For 
the optimisation of the staining procedure we generated a 
cell line microarray from paraffin-embedded cell pellets 
derived from a panel of 35 NSCLC cell lines. The A-T 
fibroblast cell line GM05849 was included as ATM-
negative control. Following IHC labelling of ATM, we 
detected specific nuclear staining in 33/35 NSCLC cell 
lines, including HCC-366, H1568, H1734, H2087 and 
H520 cells. No staining for ATM could be observed in 
GM05849 cells and in 2/35 NSCLC cell lines (5.7%) - 
H23 and H1395 (Figure 6). This is in agreement with our 
findings from western blot analyses, which demonstrated a 
loss of ATM protein expression in both cases, and confirms 
the specificity of the antibody on paraffin-embedded 
material.
ATM protein expression is frequently lost or 
reduced in human NscLc and colorectal cancer
We then proceeded with the analysis of ATM protein 
expression in human NSCLC tumour specimens (n = 
156) by IHC. The staining intensity of tumour cells was 
graded relative to the intensity observed in the tumour 
stroma (e.g. endothelial cells or fibroblasts), which was 
used as the reference to categorise moderate staining in 
each case (Figure 7a). The intensity of staining in tumour 
cells was scored independently by two observers on a 
scale of 0-3 (0 = negative, 1 = weaker than stroma, 2 = 
same as stroma or moderate, and 3 = stronger staining 
than in stroma). Specimens, in which no or only very 
weak staining was observed in the tumour stroma were 
excluded from analysis (NA; n = 19/156). Tumour 
adjacent non-cancerous lung tissue was stained to assess 
ATM protein expression in the lung parenchyma under 
physiological conditions (n = 8; Figure 7b). Lymphocytes 
and macrophages show higher ATM staining than stromal 
or lung parenchyma cells (e.g. pneumocytes) and were 
therefore, where present, considered a measure for high 
staining intensity (Figure 7b).
The scoring results are summarised in Figure 7e. A 
loss of ATM protein expression in tumour cells was evident 
in 13/137 (9.5%) cases, (Figure 7c, 7d), a proportion 
which is at the top of the range of reported ATM mutations 
in NSCLC (5.1-9.1%; [14, 15]). This could be due to the 
small sample size in our study. Moreover, in addition to 
point mutations, loss or rearrangement of the ATM gene 
locus or epigenetic silencing of gene expression could 
also contribute to the loss of ATM protein expression. 
Indeed, hypermethylation of the ATM promoter resulting 
in decreased protein levels and increased radiosensitivity 
has been described for colorectal and glioma cell lines [43, 
44]. Furthermore, studies in locally advanced breast cancer 
have shown that the ATM gene is a target for epigenetic 
silencing [45].
We further evaluated the clinical utility of this 
method for identifying cancer patients with tumoral 
loss of ATM function, by analysing ATM protein 
expression in 168 human colorectal cancer specimen. 
ATM immunohistochemistry was performed on tissue 
microarrays containing quadruple cores of each sample. 
14 of the 168 samples were excluded from analysis due 
to poor stromal staining or insufficient tumour material. 
Scoring of ATM staining intensity was performed as 
for the lung cancer specimens. Conversely to our data 
obtained in NSCLC, the proportion of tumours exhibiting 
no detectable ATM protein expression (6/154; 3.9%) in our 
study was below the reported mutation rate for ATM in this 
cancer type (approx. 11.3%) [10], raising the possibility 
that heterozygous mutations or passenger mutations 
in ATM might be common in CRC. This finding also 
highlights the importance of performing additional assays 
(e.g. IHC for ATM protein expression) and functional 
studies to support sequencing data. Notably, several of the 
cancer types with the highest reported frequency of ATM 
mutations (including bladder cancer, melanoma, CRC and 
NSCLC) also show the highest overall rate of somatic 
mutations and are therefore likely to have a higher load of 
passenger mutations [46]. 
We conclude that immunohistochemical analysis of 
ATM protein expression in tumour samples, for example in 
tumour biopsies, may be a valuable tool to identify cancer 
patients with tumoral loss of ATM function. It would not 
identify the rare cases where a mutation causes expression 
of a kinase dead protein [42], but it would allow for the 
detection of patients with loss of ATM function due to 
deletion of the gene locus, epigenetic changes or mutations 
that lead to loss of ATM expression, including truncating, 
missense or frameshift mutations, while excluding patients 
with either heterozygous or benign ATM mutations. As 
hypersensitivity to ionising radiation is one of the most 
prominent phenotypes of ATM-deficient cells [7] and 
given the observed increased sensitivity of A-T cells to 
topoisomerase inhibitors (e.g. etoposide or irinotecan) 
[16, 17], this may help to identify patients that could get 
increased benefit from these therapies. In addition to a 
potential role in the response of tumours to chemo- or 
radiotherapy, ATM-deficiency may also identify a patient 
subset that could benefit from small molecule inhibitors 
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Figure 7: Immunohistochemical analysis of ATM protein expression in lung tissue, NSCLC and CRC samples. a. 
Representative image of a lung adenocarcinoma specimen with moderate ATM protein expression, in which the nuclear staining for ATM in 
tumour cells is similar to that observed in stromal cells (arrows). Lymphocytes (arrowheads) were used as basis for strong staining intensity. 
b. Representative image of ATM IHC staining in lung tissue. Note the higher staining intensity in resident macrophages (arrowheads), 
compared to pneumocytes (arrows). c. and d. Representative images of negative (left), moderate (middle) and strong (right) staining 
for ATM in NSCLC c. and colorectal cancer d. specimens. Pictures were taken at a 400x magnification. Scale bar = 50 µm. e. Table 
summarising the results of ATM protein expression analysis in 156 human NSCLC and 168 CRC samples by immunohistochemistry. NA 
= excluded from analysis due to poor staining or tissue quality (n = 19 for NSCLC and n = 14 for CRC).
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in the context of inducing a synthetic lethal response, an 
approach for personalised cancer medicine which has 
gained much popularity in recent years [47]. IHC analysis 
of ATM expression could thus help guide the process of 
deciding on optimal cancer treatment, especially in those 
cases where radiotherapy is an option. 
MAtErIALs AND MEtHODs
cell culture
Telomerase immortalised normal bronchial 
epithelial cells (LIMM-NBE1) were kindly provided 
by Dr. Pamela Rabbitts (Leeds Institute of Molecular 
Medicine, University of Leeds, UK) [48]. GM05849 
A-T fibroblasts and COR-L105 cells were obtained from 
the Coriell Institute and the European collection of cell 
cultures, respectively. All other cell lines were obtained 
from ATCC. Cells were maintained in advanced DMEM/
F12 (Life technologies), supplemented with 5% fetal 
bovine serum (Sigma), 2 mM GlutaMAXTM and 50 U 
penicillin/50 µg/ml streptomycin (Life technologies) in 
a humidified incubator at 37°C and 7.5% CO2. Cell line 
identification was carried out by sequencing of highly 
polymorphic loci in the mitochondrial DNA as described 
in [49]. Mycoplasma testing was performed using a real-
time PCR-based assay [50].
stable knockdown of AtM
The shRNA target sequence for ATM 5’- 
GCAACATACTACTCAAAGA -3’ and the control 
sequence (shGFP) 5’- GCATGGATGAACTATACAA 
-3’ were cloned into the pSuperRetro.puro vector 
(Oligoengine). Transfections were carried out with 
Lipofectamine 2000 (Life technologies) as described by 
the manufacturer. Following a 14-day selection period 
with puromycin (Sigma), single colonies were picked, 
expanded and tested for gene knockdown using western 
blot analysis. Stably transfected cells were maintained in 
culture medium supplemented with 0.5 µg/ml puromycin. 
At least 24 h prior to any experiments, the selection 
medium was removed and replaced by puromycin-free 
culture medium.
AtM sequencing
The regions of interest from the ATM gene were 
pre-amplified from genomic DNA as previously described 
[40]. The PCR amplification was performed in 25 µl 
reactions containing 2 units MiFi DNA polymerase 
(Bioline Reagents Ltd), 0.1 µg genomic DNA and 0.5 µM 
of each primer in 1x MiFi reaction buffer. Sanger DNA 
sequencing of the resulting PCR-products was performed 
commercially (SourceBioscience). For a computational 
assessment of the possible impact of the identified amino 
acid substitutions on ATM structure and function, the 
PolyPhen-2 software tool was used [25], accessed through 
the web interface at http://genetics.bwh.harvard.edu/pph2/
index.shtml. 
Drug treatments and irradiation
NU7441 and KU55933 (Selleck chemicals) were 
prepared in DMSO (Sigma) at a concentration of 10 mM 
and stored at -20°C. Irradiations were carried out using 
a GSR D1 irradiator containing a 137Cs source (Gamma-
Service Medical GmbH). 
Western blotting
Cell lysates were prepared on ice in 50 mM Tris-
HCl pH 7.6, 137 mM NaCl, 10% glycerol, 0.1% Igepal, 
0.1% SDS, 50 mM NaF, and 1 mM sodium orthovanadate 
(Sigma), supplemented with cOmplete protease inhibitors 
(Roche), and homogenised by brief sonication. 50 µg of 
protein were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes. Antibodies used were CHK2 
Thr68 and p53 S15 (#2661, #9284; Cell Signaling 
Technologies), KAP1 S824, and SMC1 S966 (#A300-
274A, #A300-767A, #A300-050A; Bethyl Laboratories), 
p53 (#sc-126; Santa Cruz Biotechnology), NBS1 S343 
(#ab47272; Abcam), ATM S1981 (#2152-1; Epitomics 
Inc.), ATM (#04-200; Upstate Millipore), α-Tubulin and 
β-Actin (#T6074, #A1978; Sigma). After incubation 
with primary antibody overnight at 4°C, membranes 
were probed with HRP-conjugated secondary antibodies. 
Detection was carried out by chemiluminescence and 
scanning on a ChemiDocTM chemiluminescence imager 
(BioRad). Densitometric quantification of protein bands 
was performed using the ImageJ software.
clonogenic survival assay
Cells were plated in triplicate into 6-well plates and 
allowed to re-attach (depending on the cell line for 8 to 
16 h). 1 h prior to irradiation, cells were pre-incubated 
with vehicle (DMSO), NU7441 (500 nM) or KU55933 (10 
µM). 24 h post-irradiation, cells were washed with PBS 
and then incubated in drug-free culture medium to allow 
for colony formation. When colonies reached a size of ≥50 
cells (7 to 21 days depending on the cell line), they were 
fixed and stained with crystal violet/methanol, air-dried 
and counted. Data were calculated as fraction of surviving 
colonies relative to mock-irradiated vehicle control or 
inhibitor treated cells (± SEM).
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cell cycle analysis
Cells were harvested by trypsinisation and fixed 
in 70% ethanol (4oC). Cells were washed in PBS and 
incubated in PBS containing 100 µg/ml RNaseA (Qiagen) 
for 30 min at 37oC. Propidium iodide (PI, Calbiochem) 
was added at a final concentration of 20 µg/ml. DNA 
content was determined using a FACScan Flow Cytometer 
(BD Biosciences) and BD CellQuestTM Pro Software. 
The proportion of cells in G1, S or G2/M was determined 
using ModFit LT software (Verity Software House).
brdU incorporation analysis
Asynchronous cell populations were mock-
irradiated or irradiated (10 Gy). 6 h or 24 h after 
irradiation, cells were pulse-labelled with 20 µM BrdU 
(Sigma) for 20min. After harvesting and fixation in 70% 
ethanol (4oC), cells were re-suspended in 2 M HCl and 
incubated for 20 min at RT. Cells were first washed in 
PBS, then PBS containing 2% fetal bovine serum (FBS; 
Sigma), before re-suspension in PBS+2% FBS containing 
mouse anti-BrdU antibody (#347580; BD Biosciences). 
Cells were incubated in primary antibody for 90 min at 
RT, washed in PBS+2% FBS and then incubated in goat 
anti-mouse Alexa 488 secondary antibody (Invitrogen) 
for 1 h at RT, before re-suspension in PBS containing 
PI. DNA content and BrdU incorporation were measured 
using a FACSCalibur Flow Cytometer (BD Biosciences) 
and BD CellQuestTM Pro Software. Analysis of the data 
was carried out using the FlowJo software (Tree Star Inc.).
Immunohistochemistry (IHc)
IHC analysis of ATM protein expression was carried 
out on 5 µm sections of paraffin-embedded NSCLC 
specimens (ProteoGenex, Inc., and the Oxford Radcliffe 
Biobank), a lung carcinoma and normal tissue array 
(#BC041115a; US Biomax,Inc.) and tissue microarrays 
containing quadruple cores from 168 colorectal cancer 
specimen derived from the COIN clinical trial [51]. 
Antigen retrieval was performed in 10 mM Tris, 1 mM 
EDTA, 0.05% Tween20; pH 9. The EnVision+ detection 
system (#K4065; Dako) was used for staining according 
to the manufacturer’s instructions with the addition of a 
blocking step in protein blocking solution (#ab64226; 
Abcam) performed for 1 h at room temperature prior to 
the incubation of tissues in antibody solutions. Primary 
antibody specific for ATM (clone Y170; #04-200; 
Millipore) was incubated with the sections overnight at 
4°C. Stained slides were scanned (Aperio ScanScope CS) 
utilising the ScanScope software (Aperio). The staining 
intensity of tumour cells was scored relative to the 
intensity observed in the tumour stroma, which served as 
intrinsic positive control for each sample and was used as 
reference for moderate staining in each case. The intensity 
of staining was graded as negative, weak, moderate or 
strong.
Data analysis and statistics
All values are expressed as the mean ± SEM of 
at least three independent experiments unless otherwise 
stated. Drug effects on radiosensitivity were compared by 
univariate analysis of variance (ANOVA; SPSS 22.0) to 
detect statistically significant differences between drug+IR 
and IR-only treated controls. Differences were considered 
significant for values of p < 0.01.
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